si Small firms and nonprofits like KPCC struggle with technology's diversity problem By feeds.scpr.org Published On :: Wed, 21 Jan 2015 13:53:14 -0800 Mary Ann de Lares Norris is Chief Operating Officer of Oblong Industries. She brings her dog LouLou to Oblong's downtown LA headquarters.; Credit: Brian Watt/KPCC Brian WattKPCC recently reported on the tech world’s diversity problem. Technology firms face challenges in hiring diverse staffs of its coders, web developers and software engineers. It’s also a challenge at nonprofits such as Southern California Public Radio, parent of 89.3 KPCC, which has always sought to build a staff that reflects the region it serves. The section of that staff that develops the KPCC app and makes its website run is all white and mostly male. But a small talent pool means the diversity challenge is even greater for nonprofits and even smaller tech firms. “The first problem is that all of the people working for me are male,” says Alex Schaffert, the one female on KPCC’s tech team. “I’m kind of focusing on maybe getting another girl into the mix.” Schaffert can use the term “girl” because she happens to be the leader of the tech team: KPCC’s Managing Director of Digital Strategy and Innovation. Why diversity is important Schaffert recently launched the topic of diversity – or lack thereof – at a weekly meeting of her team. She expected a “stilted and awkward” discussion from the five white men on her team, but a few of them didn’t hold back. “Not having diversity represented on the team leaves us more susceptible to circular thinking and everyone sort of verifying each other's assumptions,” said Joel Withrow, who was serving at the time as KPCC’s Product Manager. “It impacts the work. It limits what you’re able to build.” Sean Dillingham, KPCC’s Design and Development Manager, said living in a diverse community is what attracted him to Los Angeles, and he wants diversity in his immediate work team, too. “When I look at other tech companies, I will often go to their ‘about us’ page, where they’ll have a page of photos of everyone, and I am immediately turned off when I just see just a sea of white dudes, or even just a sea of dudes,” Dillingham said. Big competition, small talent pool Dillingham and Schaffert are currently recruiting heavily to fill two tech-savvy positions. When a reporter or editor job opens up at KPCC, Schaffert says close to 100 resumes come in. "But if you post a programmer job, and you get three or four resumes, you may not get lucky among those resumes," she says. "There may not be a woman in there. There may not be a person of color in there." In other words, the talent pool is already small, and the diversity challenge makes it even smaller. KPCC is competing for talent with Google and Yahoo and all the start-ups on L.A.’s Silicon Beach. Schaffert’s being proactive, mining LinkedIn and staging networking events to attract potential candidates. She’s also trying to make sure KPCC’s job descriptions don’t sound like some she's seen in the tech world. "If you read between the lines, they’re really looking for someone who is male and is somewhere between 25-30 years old and likes foosball tables and free energy drinks in the refrigerator," Schaffert says. “So you read between lines, and you know that they’re not talking about me, a mother of two kids who also has a demanding career. They're talking about someone different.” Pay vs. passion Schaffert's challenges and approaches to dealing with them are similar to those of Mary Ann de Lares Norris, the Chief Operating Officer at Oblong Industries. Based in downtown Los Angeles and founded in 2006, the company designs operating platforms for businesses that allow teams to collaborate in real time on digital parts of a project. “I think technology and diversity is tough,” Norris told KPCC. She’s proud her company’s management ranks are diverse, but says only 12 percent of its engineers are female. “Pretty standard in the tech industry, but it’s not great,” Norris says. “We really strive to increase that number, and all of the other companies are also, and it's really hard.” Like Schaffert at KPCC, Norris works hard fine-tuning job descriptions and communicating that her company values diversity and work-life balance. But sometimes, it just boils down to money. "We have to put out offers that have competitive salaries,” Norris says, adding that she can’t compete with the major tech firms. "The Googles and the Facebooks of the world can always pay more than we can. So we attract people who are passionate about coming to work for Oblong. And, of course, we also offer stock options." KPCC doesn’t have the stock options, but we’ve got plenty of passion. Could that be the secret recruiting weapon for both small tech companies and nonprofits? LinkedIn recently surveyed engineers about what they look for in an employer. Good pay and work-life balance were the two top draws. Slightly more women prioritized work-life balance and slightly more men chose the big bucks. Clinical Entrepreneurship professor Adlai Wertman says that, historically, nonprofits and small businesses actually had the upper hand over big companies in recruiting minorities and women. "There’s a feeling that they’re safer, more caring environments, less killer environments, and we know that corporate America has been the bastion of white males," said Wertman. But Wertman says that advantage disappears in the tech world because of the "supply-and-demand" problem with talent. When big firms decide to focus on diversity – as some have recently — they have plenty of resources. "They’re always going to be able to pay more, and in truth they’re getting access to students coming out of these schools in ways that we as nonprofits and small companies never will," said Wertman. Wertman worked 18 years as an investment banker on Wall Street, then left to head a nonprofit on L.A.’s skid row. Now he heads the Brittingham Social Enterprise Lab Enterprise Lab at USC’s Marshall School of Business. He believes that, early on, the big companies have the best shot attracting diverse tech talent. But in the long run, much of that talent will turn back to smaller firms and nonprofits. "I think ultimately people vote with where they’re most comfortable, where 'my values align with my employer's values, and if I don’t feel those values align, then I’m going to leave,'" Wertman said. "Ultimately, I think, for a lot of women and minorities, there’s a lot of value alignment within communities that are doing good in the world." This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
si Freelancer? Avoid these '7 deadly sins' at tax time. By feeds.scpr.org Published On :: Mon, 02 Feb 2015 11:28:07 -0800 The organized freelancer will make sure the amount here is right.; Credit: Photo by Great Beyond via Flickr Creative Commons Brian WattFor freelancers, consultants, actors and other self employed people, life gets complicated this time of year. Digging around for the paperwork to fill out tax forms practically qualifies as exercise. "They have a nightmare trying to find receipts," said accountant Tristan Zier. Zier founded Zen99 to help freelancers manage their finances, including filing their taxes. His most important advice to freelancers: keep track expenses and receipts year round rather than pursuing a paper chase as April 15 nears. "When they can’t find receipts, they can’t write off their expenses," he said. "And they’re paying more money to the government instead of keeping it for themselves." Zier and others have come up with a lists of common mistakes freelancers make at tax time. Here are seven don't - or, deadly sins, for freelances at tax time: Not knowing what they owe. Zier says there are 20 different 1099 forms that get sent out to workers to track freelance gigs. One of them is the 1099-K, which only has to be sent to you by a company in paper form if you make over $20,000. "People think, 'Great, no paper form, no taxes on that," says Zier. "Big mistake there. You still have to self-report the income." Not knowing WHEN they owe. For freelancers who owe more than $1,000 in taxes for a year, tax time comes more often than just April 15. They have to pay taxes quarterly. But then it's not coming out of paychecks like it does for permanent employees. Not tracking and writing off the right types of business expenses. Zier says many freelancers fail to realize they can write off part of their cell phone bill as a business expense. Expenses vary by the type of work. "A rideshare driver's biggest expense will be related to their car, while a web developer's biggest expense might be their home office," Zier says. "Figuring out what expenses are important to your type of work is important is maximizing your tax savings." Writing off personal expenses. This goes back to that cell phone. If you use the same phone for personal and business purposes, don't be tempted to write the whole bill off. Estimate the amount you use it for your work. The same goes for your vehicle. Don't go trying to write off miles driven to the beach. The Double No-No: counting expenses twice. Speaking of vehicles, Zier says most people use the Standard Mileage Rate ($0.56/mile for 2014), which factors in gas, repairs and maintenance and other costs like insurance and depreciation. But if you use this rate, you can't also expense your gas receipts and repair bills. Employee AND employer. At lifeofthefreelancer.com, financial consultant Brendon Reimer reminds freelancers they play both roles. For regular employees, Federal, State, and payroll taxes are withheld from a paycheck, and distributed on the employee’s behalf. It's how Social Security and Medicare are funded. The IRS mandates that the employer must pay half of every employee’s payroll tax, and the employee is responsible for the other half. Independent contractors have to handle both halves. "The IRS does give you a small benefit by letting you deduct the half that you pay yourself as a business expense," Reimer writes. Zier said the freelancer's sin here is believing he or she pays more taxes than the regular working stiff. Not keeping adequate records. The IRS requires you to keep proof of all business receipts, mileage, etc. If you can't show these, the IRS could refute the expense and force you to pay back taxes. Zier says the good news is there are other ways to prove expenses if you've lost the receipt. A bank or credit card statement with the date and location might do the trick. "The IRS is surprisingly accommodating if you are doing your best," Zier says. "If you're being a headache, they're going to be a headache as well." In separate reports, Zen99 and the consumer finance web site nerdwallet ranked Los Angeles the best city for freelancers. Each considered housing and health care costs, the percentage of freelancers in an area as factors. Zier said even before the sharing economy began to take off, the entertainment industry and growing tech scene were already strong sources of freelance gigs in L.A. "Even back in 2012, L.A. had twelve percent of people report themselves as self-employed on the Census," Ziers said. "You know your Ubers and companies like that are really bringing a lot of attention to the contractor market, but it was a very robust community before." This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
si Shared tech workspaces spread beyond sands of Silicon Beach By feeds.scpr.org Published On :: Fri, 06 Feb 2015 05:00:02 -0800 People using a coworking space.; Credit: Cross Campus Brian WattIn a sign of increased desire of professionals to work remotely, the successful Santa Monica shared workspace Cross Campus is opening a second location in Pasadena later this month, and the company hopes to open eight others in Southern California and beyond in the next two years. Dubbed by one user as the “nerve center” of the Silicon Beach tech scene, Cross Campus opened its membership-based workspace facility in Santa Monica in 2012. But co-founder Ronen Olshansky said the shared workspace phenomenon isn't limited to coders. "Fewer and fewer people are making the traditional drive into the corporate office," Olshansky said. "They're working remotely as professionals, going off on their own as freelancers, or they're starting their own companies as entrepreneurs." A forecast from Forrester Research says that 43 percent of workers will telecommute by 2016, compared to estimates of about a quarter of the workforce telecommuting last year. Olshansky said that, for many people, working from home or in a coffee shop isn't productive. That's led shared workspaces to pop up in Los Angeles, Culver City and Santa Monica. Among them: Maker City L.A., WeWork, NextSpace, Coloft and Hub LA. Los Angeles-based tech investor David Waxman said these kind of shared spaces are crucial for the early stages of tech ventures. "When you’re just starting out, and capital is very scarce, having not to commit to an entire office but having part of an office is very important," Waxman said. “There comes a collective energy when a bunch of entrepreneurs get together in the same space, even if they’re not working on the same project." And he said Pasadena is a good choice for a shared workspace. "It is the home of Caltech, the Arts Center, and IdeaLab — probably the world’s first tech incubator — started there," he said. But he said the need isn't limited to Pasadena. "In Silver Lake, in South Pasadena, in Glendale, you see a lot of little pockets of people getting together, and as soon as there’s a critical mass, we’ll see co-working spaces like Cross Campus come into being," said Waxman, who named his investment firm TenOneTen after the two freeways that connect Santa Monica and the Westside to Pasadena. Alex Maleki of IdeaLab in Pasadena is happy a well-known company is opening up in his city. "Anything that helps attract talent and capital to the region," Maleki said, "is absolutely fantastic." This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
si Ports see worst congestion since 2004 because of work stoppage By feeds.scpr.org Published On :: Mon, 09 Feb 2015 16:31:33 -0800 In this Jan. 14, 2015, photo, shipping containers are stacked up waiting for truck transport at the Port of Los Angeles.; Credit: Damian Dovarganes/AP Ben BergmanThe Ports of Los Angeles and Long Beach reopened Monday after ship loading and unloading was suspended this weekend because of a long-running labor dispute, which caused the worst delays the ports have seen in more than a decade. The stoppage led to a queue of 31 ships, according to Kip Louttit, Executive Director of the Marine Exchange of Southern California, the agency that manages ship traffic. “It’s quite unusual,” said Louttit. There was a 10-day lockout at the ports in 2002, and an eight-day strike by port clerks in 2012, but even during those standoffs, the queue never exceeded 30 vessels. The last time that happened was in 2004, because of staffing shortages at the Union Pacific Railroad. Some 65 ships were anchored, "backed up halfway down to San Diego, like 50 miles down the coast," Art Wong, spokesperson for the Port of Long Beach, told JOC.com, a container shipping and international supply chain industry website. By Monday afternoon, the situation had improved some: 24 vessels were waiting to dock. Louttit says all those ships waiting at sea means cargo is not getting where it needs to be. “We had an automaker from the Midwest stop by, trying to get an idea of what the flow would be, because their plants are running out of parts to make cars,” he said. Los Angeles Councilman Joe Buscaino, who supports the dockworkers union, called on both sides to reach an agreement quickly. To underscore the delays the dispute is having, he travelled a mile and a half out to sea Monday morning to count the number of anchored ships for himself. He posted a video of his trip on Youtube: This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
si Genetic diversity couldn't save Darwin's finches By feedproxy.google.com Published On :: 2019-08-27T07:00:00Z Full Text:A National Science Foundation-funded study found that Charles Darwin's famous finches defy what has long been considered a key to evolutionary success: genetic diversity. The research on finches of the Galapagos Islands could change the way conservation biologists think about a species' potential for extinction in naturally fragmented populations. Researchers examined 212 tissue samples from museum specimens and living birds. Some of the museum specimens in the study were collected by Darwin himself in 1835. Only one of the extinct populations, a species called the vegetarian finch, had lower genetic diversity compared to modern survivors. Specifically, researchers believe a biological phenomenon called sink-source dynamics is at play in which larger populations of birds from other islands act as a "source" of immigrants to the island population that is naturally shrinking, the "sink." Without these immigrant individuals, the natural population on the island likely would continue to dwindle to local extinction. The immigrants have diverse genetics because they are coming from a variety of healthier islands, giving this struggling "sink" population inflated genetic diversity.Image credit: Jose Barreiro Full Article
si Physicists demonstrate silicon's energy-harvesting power in study By feedproxy.google.com Published On :: 2019-08-28T07:00:00Z Full Article
si Salt marshes' capacity to sink carbon may be threatened by nitrogen pollution By feedproxy.google.com Published On :: 2019-08-28T07:00:00Z Full Article
si Astronomers find a golden glow from a distant stellar collision By feedproxy.google.com Published On :: 2019-08-30T07:00:00Z Full Text:On August 17, 2017, scientists made history with the first direct observation of a merger between two neutron stars. It was the first cosmic event detected in both gravitational waves and the entire spectrum of light, from gamma rays to radio emissions. The impact also created a kilonova -- a turbocharged explosion that instantly forged several hundred planets’ worth of gold and platinum. The observations provided the first compelling evidence that kilonovae produce large quantities of heavy metals, a finding long predicted by theory. Astronomers suspect that all of the gold and platinum on Earth formed as a result of ancient kilonovae created during neutron star collisions. Based on data from the 2017 event, first spotted by the Laser Interferometer Gravitational-wave Observatory (LIGO), astronomers began to adjust their assumptions of how a kilonova should appear to Earth-bound observers. A team of scientists reexamined data from a gamma-ray burst spotted in August 2016 and found new evidence for a kilonova that went unnoticed during the initial observations.Image credit: NASA/ESA/E. Troja Full Article
si Using Wi-Fi like sonar to measure speed and distance of indoor movement By feedproxy.google.com Published On :: 2019-08-30T07:00:00Z Full Article
si Using AI to track birds' dark-of-night migrations By feedproxy.google.com Published On :: 2019-09-03T07:00:00Z Full Article
si New way for bridges to withstand earthquakes: Support column design By feedproxy.google.com Published On :: 2019-09-04T07:00:00Z Full Text:Bridges make travel faster and more convenient, but, in an earthquake, these structures are subject to forces that can cause extensive damage and make them unsafe. Now civil and environmental engineer Petros Sideris of Texas A&M University is leading a National Science Foundation (NSF)-funded research project to investigate the performance of hybrid sliding-rocking (HSR) columns. HSR columns provide the same support as conventional bridge infrastructure columns but are more earthquake-resistant. HSR columns are a series of individual concrete segments held together by steel cables that allow for controlled sliding and rocking. This allows the columns to shift without damage, while post-tensioning strands ensure that at the end of an earthquake the columns are pushed back to their original position. Conventional bridges are cast-in-place monolithic concrete elements that are strong but inflexible. Structural damage in these bridge columns, typically caused by a natural disaster, often forces a bridge to close until repairs are completed. But bridges with HSR columns can withstand large earthquakes with minimal damage and require minor repairs, likely without bridge closures. Such infrastructure helps with post-disaster response and recovery and can save thousands in taxpayer dollars. In an earthquake, HSR columns provide "multiple advantages to the public," Sideris said. "By preventing bridge damage, we can maintain access to affected areas immediately after an event for response teams to be easily deployed, and help affected communities recover faster. In mitigating losses related to post-event bridge repairs and bridge closures, more funds can be potentially directed to supporting the recovery of the affected communities." According to Joy Pauschke, NSF program director for natural hazards engineering, "NSF invests in fundamental engineering research so that, in the future, the nation's infrastructure can be more resilient to earthquakes, hurricanes, and other forces of nature."Image credit: Texas A&M University Full Article
si V Capital partners Cross River Bank to obtain banking licence in Malaysia By feedproxy.google.com Published On :: Tue, 28 Apr 2020 13:35:00 +0200 Malaysia-based advisory company V Capital has teamed up... Full Article
si The People's Bank of China expands fintech regulations to six new cities By feedproxy.google.com Published On :: Wed, 29 Apr 2020 12:36:00 +0200 The People’s Bank of China (PBoC) has announced that it is expanding its financial technology regulations to... Full Article
si Looking for suggestions of music and video software By www.bleepingcomputer.com Published On :: 2020-04-28T16:56:21-05:00 Full Article
si Background Noise When Using Mic (Even with RTX Voice) By www.bleepingcomputer.com Published On :: 2020-04-29T16:05:05-05:00 Full Article
si Converting Quicktime Video Screen Capture to smaller file sizes By www.bleepingcomputer.com Published On :: 2020-05-02T10:15:33-05:00 Full Article
si Hey there! Are you using WhatsApp? Your account may be hackable By feedproxy.google.com Published On :: Mon, 20 Apr 2020 09:30:38 +0000 Can someone take control of your WhatsApp account by just knowing your phone number? We ran a small test to find out. The post Hey there! Are you using WhatsApp? Your account may be hackable appeared first on WeLiveSecurity Full Article Social Media
si Work from home: Should your digital assistant be on or off? By feedproxy.google.com Published On :: Mon, 20 Apr 2020 13:00:50 +0000 Being at your beck and call is central to the "personality" of your digital friend, but there are situations when the device could use some time off The post Work from home: Should your digital assistant be on or off? appeared first on WeLiveSecurity Full Article COVID-19
si Professional data leakage: How did that security vendor get my personal data? By feedproxy.google.com Published On :: Tue, 05 May 2020 09:30:55 +0000 …and why are they selling it to other security vendors and product testers? The post Professional data leakage: How did that security vendor get my personal data? appeared first on WeLiveSecurity Full Article Privacy
si Almost a million WordPress websites targeted in massive campaign By feedproxy.google.com Published On :: Wed, 06 May 2020 19:18:12 +0000 An unknown threat actor is exploiting vulnerabilities in plugins for which patches have been available for months, or even years The post Almost a million WordPress websites targeted in massive campaign appeared first on WeLiveSecurity Full Article Vulnerability
si Can I still be infected with a virus if the website is blocked? By www.bleepingcomputer.com Published On :: 2020-04-11T15:45:54-05:00 Full Article
si Should I be concerned that "WsAudioDevice_383S(1)" is UNSIGNED? By www.bleepingcomputer.com Published On :: 2020-04-11T18:41:45-05:00 Full Article
si Legitimate sites infected? By www.bleepingcomputer.com Published On :: 2020-04-12T14:44:14-05:00 Full Article
si Programs can completely ignore NTFS permissions By www.bleepingcomputer.com Published On :: 2020-04-21T02:46:57-05:00 Full Article
si Coda Payments partners Riot Games for payments services across Southeast Asia By feedproxy.google.com Published On :: Mon, 04 May 2020 13:36:00 +0200 Coda Payments and Riot Games have announced that players... Full Article
si Lyft's ride-hailing business is down 70% due to COVID-19 By feedproxy.google.com Published On :: Thu, 07 May 2020 11:40:00 +0200 The Verge has revealed that Lyft’s ride-hailing business... Full Article
si OneSignal launches Shopify App for customer engagement By feedproxy.google.com Published On :: Thu, 07 May 2020 12:44:00 +0200 Full Article
si Why These 2 Investment Professionals Say This Telemedicine Company Is One of Their Top Picks By feedproxy.google.com Published On :: Tue, 28 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/28/2020 As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada.News Flash: On May 7, CloudMD announced that it is partnering with IDYA4 Corp. for it to resell the health technology firm's Livecare technology in the U.S.. Read more here. News Flash: On May 4, CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. Read more here. As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic, telemedicine has taken off. Two investment professionals, Bruce Campbell and Keith Schaefer, have called CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE), a small-cap Canadian telemedicine firm, a top pick. Bruce Campbell, founder and portfolio manager of Stonecastle Investment Management, spoke about CloudMD on April 27 on BNN: "The first top pick is CloudMD Software, a technological medical play. We've tried to look at opportunities that are really going to be able to take advantage of Covid and this is one of the ones that we think is; what they do is telemedicine. "The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." - Keith Schaefer If you look back at a year ago, where everyone had to go to the doctor, and now all of the different provinces have opened up billing codes, so that now we don't have to go into a doctor's office. We can do a virtual doctor's visit and the doctor gets paid just like they do with an in-house appointment. Obviously with everything that has happened with this crisis, people really don't want to go into a doctor's office and they need a prescription renewal or something like that. If you look at CloudMD's peers in the U.S., there is a company called Teladoc, which is a big U.S. company that does the same thing. Obviously, the size of the market is different, but the multiple it trades at is multiple times higher than where CloudMD is. CloudMD is just starting to gain adoption. They started off here in BC, they have moved to Ontario, and they are going to be rolling out really across the country, so tons of opportunity for a company like this. They will probably change the way that we view our doctor and our healthcare visits going forward." Keith Schaefer, editor and publisher of Oil & Gas Investments Bulletin, is also following CloudMD, and wrote: "An entirely newand highly profitableindustry is being borne out in 2020TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play TeleHealth. It's growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical RecordsEMRsystem. It has MULTIPLE revenue streams and it just moved into Canada's largest marketOntariosetting up an even faster growth rate. The recent spread of coronavirus is only accelerating this. Covid-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don't want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth. TeleHealth companies in Canada are getting paid more money for services than bricks-and-mortar clinics, and have a fraction of the costs. Doctors want more of it, patients want more of it, government wants more of itand the Market REALLY wants more of it. Everybody wins here; there is no downside. The rapid scale-up and profitability is key for investors. CloudMD is established, growing quickly and trading at a fraction of its peers. The average multiple of competitors in the sector trade at 5-7x revenue, and CloudMD is trading way below that at 2.5x per revenue. But realize that the Canadian use of telemedicine is still just a fraction of where it is in the U.Sso the quick, early upside is even bigger. The market desperately wants to own TeleHealth right now. I see CloudMD as the best way to do that in the junior sector (where the leverage is!). For this stock to have a major run all that needs to happen is for institutional investors to wake-up to the fact that the company exists. That's happening now with the company entering the province of Ontariowhich has 14.5 million peopleover one-third of Canada's population. CloudMD is a fully integrated health care companykind of like a hospital-in-the-sky. They do have five bricks-and-mortar clinics, but they also own their own EMRElectronic Medical Recordssystem that operates in eight provinces and is used by over 3,000 doctors and is supported by an in-house 25 person development team. They have their own CloudMD appwhich has over 100,000 registered patients already. The EMR gives CloudMD a recurring monthly revenue stream, which The Street loves. The app gives them high-margin fees from doctors, specialists and groups like massage therapists & counselors. These people are revenue, not costs. As I said, full hospital-in-the-sky. Multiple revenue sources with lower costs. To schedule a virtual doctor's appointment all that a patient has to do is download the free CloudMD app and then arrange an appointment with one of the doctors. There is zero charge for the patient and they can see a doctor very quickly. CloudMD can scale up the number of patients VERY quicklyand they are. Every aspect of healthcare that's very fractured and disjointed will now be in the one CloudMD ecosystem. Everyone wins with this system. Patients, doctors, the medical system, society, even investors. Everyone. Doctors who have signed up with CloudMD work remotely from home or wherever they are (like their winter home down south). The rapid scale-up potential excites me. CloudMD can add in unlimited number of doctors and patientsso it has a virtually unlimited ability to scale quickly with little incremental cost. Profit margins are wide and there is no cap on the number of customers that can be handled. After a patient has an appointment, CloudMD bills the government directly just like every bricks-and-mortar clinic in Canada does. CloudMD records 100% of the revenue and gets to keep 30% of the billing for every patient that is seen through telemedicine, which is actually 10% more than what a bricks-and-mortar clinic receives. That is because the governments are trying to push TeleHealth. The doctor gets the other 70% and doesn't have to deal with any headaches of commuting or running a business. Without the overhead of a bricks-and-mortar clinic, AND more revenue, CloudMD will be much more profitable than traditional healthcare stocks. Faster scale, more cash flow. And they just entered Canada's largest market. This is the right stock in the right market at the right time. That's the great thing about this business model. It's very scalable, very easy, and it grows very quickly. CloudMD has been growing its recurring SAAS (Software-as-a-Service) revenue by 30% YoY with its EMR system. But this year the company is expecting that doctor growth to be much much higherwith a new full time sales team and the coronavirus pandemic. SaaS revenue is highly lucrative! The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." Read Keith Schaefer's entire article here. Watch Bruce Campbell of StoneCastle Investments share his top picks: CloudMD, Lightspeed and Viemed. Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Keith Schaefer: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: CloudMD. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: CloudMD. My company has a financial relationship with the following companies mentioned in this article: None. Additional disclosures are listed below. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with CloudMD. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of CloudMD. Please click here for more information. 3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy. 4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of CloudMD, a company mentioned in this article. Additional Disclosures Keith Schaefer Disclosures: CloudMD has reviewed and sponsored this article. The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom. Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Keith Schaefer is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity. Bruce Campbell, Stonecastle Investment Management: A guest firm/affiliate holds a position in CloudMD. There is no guest position held, members of his household do not hold positions and CloudMD is not an investment banking client. ( Companies Mentioned: DOC:CSE; DOCRF:OTCQB; 6PH:FSE, ) Full Article
si Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results' By feedproxy.google.com Published On :: Wed, 22 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/22/2020 The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report.In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can-Fite BioPharma Ltd.'s (CANF:NYSE.MKT) Phase 2 trial of Namodenoson for nonalcoholic fatty liver disease with or without nonalcoholic steatohepatitis "look pretty good." He added that "the consistency of the data from the studies (preclinical and clinical), should support business development interest." Dawson James has a $9 per share target price on Can-Fite; the stock is currently trading at around $1.75 per share. Kolbert recapped the study design and provided the results. This purpose of this multicenter, randomized, double-blinded, placebo-controlled trial involving 60 patients was to determine dose efficacy and safety. Patients were treated twice a day with either 12.5 milligrams or 25 milligrams of oral Namodenoson or a placebo for 12 weeks. The primary endpoint was effect on inflammation, measured by mean percent change from baseline in alanine transaminase blood levels and safety. The second endpoints included the percent change from baseline in liver fat, as determined by MRI proton density fat fraction. In terms of safety, study participants tolerated Namodenoson at both doses, and no adverse events were reported. Otitis media occurred in two patients but was deemed to be unrelated to the drug. The four other events that occurred that were drug related were mild and self-limited. Regarding efficacy of Namodenoson, Kolbert noted that "for a small Phase 2 exploratory study, there appears to be a significant efficacy signal." Kolbert provided updates on other Can-Fite clinical trials. The company's COVID-19 trial is now designed. Plans call for it to be randomized, open label, and double armed with Piclidenoson administered plus standard supportive care, compared to standard supportive care alone, in 40 hospitalized COVID-19-infected patients with moderate to severe symptomatic disease. Patients are to be randomized at a 1:1 ratio to one of the trial arms and treated for up to four weeks. The primary efficacy measures will be time to resolution of viral shedding, time to resolution of clinical symptoms, respiratory function, need for ventilatory support and overall mortality. Piclidenoson, Can-Fite's lead drug candidate, also is in Phase 3 in two indications: moderate to severe rheumatoid arthritis (the ACROBAT study) and moderate to severe plaque psoriasis (the COMFORT study). Enrollment for both trials is more halfway complete. In both, Piclidenoson "hold great promise as alternative therapies with what appears to be a more favorable side effects profile," Kolbert commented. Dawson James has a Buy rating on Can-Fite BioPharma. Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. Disclosures for Dawson James Securities, Can-Fite BioPharma Ltd., April 20, 2020, The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering. Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities. Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analysts compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. ( Companies Mentioned: CANF:NYSE.MKT, ) Full Article
si Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings By feedproxy.google.com Published On :: Mon, 27 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/27/2020 Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients.Avadel Pharmaceuticals Plc (AVDL:NASDAQ) today announced "positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy." The firm pointed out that it met all three of the co-primary efficacy endpoints in the study for each of three dosage levels which it claims demonstrates "highly significant, clinically meaningful improvements on the Maintenance of Wakefulness Test, Clinical Global Impression-Improvement and mean weekly cataplexy attacks." The company's Chief Medical Officer Jordan Dubow, M.D., commented, "We are excited to see these positive topline data from the REST-ON study, where all three dose levels of once-nightly FT218 demonstrated a statistically significant and clinically meaningful improvement on the measures of the two prominent symptoms of narcolepsy, as well as an improvement in overall functioning compared to placebo...Once-nightly FT218 delivered a clinically meaningful response within three weeks of treatment initiation, which was sustained through each treatment period...We think once-nightly FT218, if approved, has the potential to be a meaningful contributor to patient care." Avadel Pharma's CEO Greg Divis remarked, "The successful outcome of the REST-ON study strengthens our belief that, if approved, once-nightly FT218 has the potential to be a significant advancement for patients in the estimated $1.7 billion twice-nightly sodium oxybate market. Our proprietary market research with physicians and patients informs us that there is a strong interest in a once-nightly sodium oxybate formulation. We look forward to sharing the results from the REST-ON study with the FDA and progressing toward a potential approval that would allow us to bring this important treatment to the patients who need it most. If approved, FT218 would be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy." The REST-ON study is a double-blind, randomized, placebo-controlled Phase 3 trial to assess the efficacy and safety of once-nightly FT218, a formulation of sodium oxybate using Avadel's proprietary Micropump technology for extended-release oral suspension in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company stated that 212 patients were enrolled in the study and result "showed that the 9 g dose of once-nightly FT218 demonstrated a highly significant and clinically meaningful improvement compared to placebo across all three co-primary endpoints." The company advised that FT218 has been granted Orphan Drug Designation from the U.S. FDA for the treatment of narcolepsy. The firm added that the designation was granted on basis that FT218 may be clinically superior to a formulation of sodium oxybate that is already approved by the FDA for the same indication. Avadel Pharmaceuticals is biopharmaceutical company headquartered in Dublin, Ireland. The company's primary focus is on the development and potential FDA approval for FT218, which just completed its Phase 3 REST-ON clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness and cataplexy. The firm also develops and markets sterile injectable drugs for use in hospital settings. Avadel started off the day with a market capitalization of around $456.2 million with approximately 46.4 million shares outstanding and a short interest of about 14.00%. AVDL shares opened more than 34% higher today at $13.30 (+$3.37, +34.28%) over Friday's $9.83 closing price and reached a new 52-week high price this morning of $13.49. The stock has traded today between $11.90 and $13.49 per share and is currently trading at $12.27 (+$2.44 +24.82%). Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice. ( Companies Mentioned: AVDL:NASDAQ, ) Full Article
si Episode 955 Scott Adams: Extra Cussing Tonight. Put the Kids to Bed. Close Your Windows, Get Under the Covers By feed.dilbert.com Published On :: Tue, 05 May 2020 03:43:39 +0000 My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Hydroxychloroquine as a game-changer Winning a Pulitzer A logical back to work metric Yearly flu death numbers aren’t real Remdesivir does NOT change survival rate The FBI’s reputation If you would like my channel to have a wider audience and higher production quality, please donate […] The post Episode 955 Scott Adams: Extra Cussing Tonight. Put the Kids to Bed. Close Your Windows, Get Under the Covers appeared first on Scott Adams' Blog. Full Article Podcast Carlos Del Rio Coronavirus Hydroxychloroquine Jeremy Faust MD MS politics president trump Pulitzer Prize Remdesivir Scott Adams
si Episode 956 Scott Adams: Come Sip the News By feed.dilbert.com Published On :: Tue, 05 May 2020 16:18:44 +0000 My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: The revised death model Reaching a new level of contempt for CNN coverage Sean Hannity wants armed protesters to reconsider Chinese drones being used by US law enforcement? Civil disobedience is coming and growing If you would like my channel to have a wider audience […] The post Episode 956 Scott Adams: Come Sip the News appeared first on Scott Adams' Blog. Full Article Podcast Bill Gates Civil Disobedience Coronavirus Hydroxychloroquine Joe Biden politics president trump Scott Adams Sean Hannity
si Amex to help cardholders save on spending amid coronavirus crisis By feedproxy.google.com Published On :: Tue, 14 Apr 2020 13:00:00 +0200 American Express has Full Article
si ECOMMPAY offer 0 percent on card processing fees during COVID-19 pandemic By feedproxy.google.com Published On :: Thu, 23 Apr 2020 15:12:00 +0200 Payment service provider and direct card acquirer ECOMMPAY have... Full Article
si Solar Energy Firm Signs Large Deal for New York Project, 1215 Times Its Average Size By feedproxy.google.com Published On :: Thu, 02 Apr 2020 00:00:00 PST This project, along with two other new projects, increases the company's order backlog by 65%. Full Article UGE:TSX.V; UGEIF:OTCQB
si Oil Price and WPX Energy Shares Rebound as President Trump Tweets He Expects Russia and Saudi Arabia to Reach Deal By feedproxy.google.com Published On :: Thu, 02 Apr 2020 00:00:00 PST Shares of WPX Energy traded 25% higher after President Trump tweeted that he expected a deal between Russia and Saudi Arabia to scale back oil production. Full Article
si Kraton Share's Rise on Positive Q1/20 Earnings Report By feedproxy.google.com Published On :: Thu, 30 Apr 2020 00:00:00 PST Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19. Full Article
si ION Geophysical Shares Trade 70% Higher after Reporting 53% Rise in Q1 Sales By feedproxy.google.com Published On :: Thu, 07 May 2020 00:00:00 PST Shares of ION Geophysical traded higher after the company reported Q1/20 financial results that included a 53% year-over-year increase in revenue. Full Article
si A new tool to help predict species invasiveness By ec.europa.eu Published On :: Wed, 1 Jun 2011 11:59:41 +0100 There is a common assumption that plant species are more inclined to thrive in a non-native community than a native one, sometimes becoming 'invasive'. However, this behaviour is likely to be quite unusual and invasive alien plants are actually an important exception, according to a new study. Much can be learned from the population of a species 'at home' and should be included in official assessment criteria. Full Article
si Impact of landfill caps on leachate emissions ??? an Austrian case study By ec.europa.eu Published On :: Fri, 26 Aug 2011 11:50:44 +0100 Municipal solid waste (MSW) landfills, which consist of everyday consumer items, are potential long-term sources of emissions that could threaten the environment and human health if they are not managed carefully after closure. New research has presented a methodology to estimate future emission levels for closed MSW landfills and the impact of different aftercare strategies. Full Article
si Urban vegetation could be an undervalued carbon sink By ec.europa.eu Published On :: Thu, 13 Oct 2011 16:17:35 +0100 Urban vegetation could have been overlooked as valuable above-ground carbon storage, according to researchers. They estimated that 231,521 tonnes of carbon were stored in above-ground vegetation in a UK city, the majority of which (97 per cent) in trees. This was 10 times the amount estimated from national figures for the same city area. Full Article
si New holistic method for assessing Natura 2000 landscapes By ec.europa.eu Published On :: Thu, 13 Oct 2011 16:19:21 +0100 High quality landscape assessments of areas protected under the Natura 2000 network are critical for effective long-term management plans. In a recent study, scientists have presented a integrated assessment of a Natura 2000 site in Sicily, Italy, which not only considers preservation of environmental features, as required by Natura 2000, but also human features, such as places of historical interest or industrial activity. Full Article
si Regulatory barriers to industrial symbiosis in metal sector By ec.europa.eu Published On :: Thu, 5 Jul 2012 14:41:01 +0100 A new study has investigated the possibility of a regional industrial symbiosis of metal industries across the Sweden-Finland border. The analysis suggests that it is technologically feasible, but that regulatory support may be inefficient, particularly with respect to changing the status of a waste product to a by-product. Full Article
si Intensive agriculture leaves lasting legacy on soil health By ec.europa.eu Published On :: Thu, 5 Jul 2012 14:42:18 +0100 The long-lasting and negative effects of intensive farming on soils persist even where complex animal communities have been reintroduced to the soil in attempt to restore the natural balance, according to a recent study. The findings highlight the possible effects of historical land use on soils' ability to deliver ecosystem services. Full Article
si Global air quality to worsen significantly under ???business as usual??? human activity By ec.europa.eu Published On :: Mon, 12 Nov 2012 11:47:09 GMT Global air quality will significantly deteriorate by 2050 unless further steps are taken to cut current emissions from human activities, according to recent research. Most people around the world will be affected by worsening air quality with hotspots of particularly poor air occurring in China, northern India and the Middle East. Full Article
si The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million to By ec.europa.eu Published On :: Thu, 7 Feb 2013 11:44:52 GMT The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million tonnes of construction waste into different materials. The researchers suggest that the study provides an important reference for other countries working to minimise construction waste. Full Article
si A standard method to assess effective measures for contaminated site remediation By ec.europa.eu Published On :: Thu, 21 Feb 2013 11:26:41 GMT A standardised method to help choose the most cost-effective measures to remediate contaminated sites has been developed by Austrian researchers. The method takes into account a wide range of factors, including the principles of sustainability. Full Article
si Urban wasteland areas can be re-developed as rich ecological sites By ec.europa.eu Published On :: Thu, 7 Mar 2013 12:41:54 GMT Researchers in Berlin have demonstrated that urban wasteland areas can be used as suitable habitats for a range of grassland species. Using simple and cost-effective measures to sow grassland seed mixtures, they found that such areas flourished despite poor soil conditions and high levels of impact from people. Full Article
si Product design screening method helps reduce toxic materials in consumer goods By ec.europa.eu Published On :: Thu, 11 Apr 2013 10:00:25 +0100 A recent study has described a simple method to screen the toxicity of materials used in consumer products. Using utility meter products as examples, the study found, for example, that stainless steel and polyvinyl chloride (PVC) had high toxicity potentials and suggests less toxic, but equally effective and priced, alternatives that could be used instead. Full Article